ESMO Gastrointestinal Oncology
Издатель: Elsevier · ISSN 2949-8198 · 58 статей
- Risk factors for second primary esophageal cancer after head and neck squamous cell carcinoma: a systematic review and meta-analysis
- Dynamic HER2 reassessment and precision sequencing after trastuzumab in HER2-positive advanced gastric cancer
- Claudin 18.2 expression—concordance between primary and metastatic lesions in gastric and gastroesophageal adenocarcinomas: a systematic review and meta-analysis
- Early-onset adenocarcinomas of the distal esophagus, gastroesophageal junction, and stomach: a systematic review and meta-analysis of 45 studies
- RAS-targeted therapies for pancreatic cancer
- Sex-based survival differences in patients with untreated advanced oesophageal squamous cell carcinoma receiving chemotherapy and immune checkpoint inhibitors: a meta-analysis
- Recent advances in loco-ablative therapies for liver cancers
- Transarterial chemoembolization (TACE) with or without immune checkpoint inhibitors in unresectable hepatocellular carcinoma: a meta-analysis of randomized clinical trials☆
- Dual versus single-agent immune checkpoint inhibitor therapy in microsatellite instability-high metastatic colorectal cancer: an analysis based on reconstructed patient data
- Prognostic relevance of secondary actionable fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab
- Strategies to overcome barriers in access to cancer treatment in Latin America: a regional perspective
- Microsatellite instability testing in gastrointestinal cancers: current standards, challenges and future directions
- Expanding the ESMO-MCBS: integrating organ preservation into clinical benefit assessment in rectal cancer
- TROP2 expression in gastric and GEJ adenocarcinomas: associations with clinicopathological features, biomarkers, and treatment outcomes
- Care delivery among patients with early-onset versus average-onset cholangiocarcinoma: a nationwide retrospective analysis
- Patterns of presentation and diagnostic delays in biliary tract cancers: a real-world European study
- Consensus recommendations for the management of locally advanced rectal cancer
- Real-world efficacy, safety, and treatment continuity of fruquintinib in Japanese patients with colorectal cancer: a multicentre retrospective study
- Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first-line therapy
- Real-world outcomes of first-line gemcitabine–platinum plus an immune checkpoint inhibitor and subsequent treatment with matched targeted therapy in biliary tract cancer
- Comprehensive characterisation of patients with colorectal cancer and permanently liver-limited disease
- Differences in treatment and outcomes between young and older patients with colorectal cancer liver metastases: an AmCORE-based study
- Transarterial chemoembolization combined with immunotherapy-based treatments versus TACE alone in unresectable hepatocellular carcinoma: a systematic review and network meta-analysis
- Beyond PD-L1 and HER2: emerging predictive biomarkers in gastroesophageal tumors
- Reprogramming the tumor microenvironment in MSS CRC: the role of TKIs in combination with immunotherapy
- GIST in Turner Syndrome
- Intra- and intertumoral discordance of Claudin-18.2: a systematic review and meta-analysis
- Prevention and management of hormonal crisis in neuroendocrine tumors undergoing PRRT (peptide receptor radionuclide therapy): a systematic review